Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 in combination with standard chemotherapy in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) therapy. The FDA’s support for the amendments allows the company to refine the study design to better target patients who may derive the most benefit. This regulatory milestone is significant for Lantern Pharma as it advances its precision oncology pipeline, leveraging its proprietary RADR platform and AI capabilities to identify patient populations most likely to respond to its therapies.
Lantern Pharma is a clinical-stage precision oncology company using artificial intelligence and machine learning to transform cancer drug development. Its pipeline includes LP-184, LP-284, and LP-300, with LP-300 being the focus of the HARMONIC trial. The company also operates a commercial AI platform, Zeta.ai, for the biomedical community. This FDA feedback potentially accelerates the development timeline for LP-300 and underscores the importance of biomarker-driven approaches in lung cancer treatment. The full press release is available at https://ibn.fm/Rxklm.
For investors, this development highlights Lantern Pharma’s progress in navigating regulatory requirements for a novel therapy addressing an unmet medical need. The focus on never-smokers with specific EGFR mutations positions LP-300 as a potential targeted therapy in a niche but underserved patient population. More information about Lantern Pharma can be found at https://ibn.fm/LTRN.
